Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
You are here: Home / FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July
Market News and Views
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.